Doliver Advisors
ONCY icon

Doliver Advisors’s Oncolytics Biotech ONCY Stock Holding History

Doliver Advisors’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$66.8K Hold
100,000
– – 0.01% 181
2026
Q2 		$95K Hold
100,000
– – 0.02% 190
2026
Q1 		$84.9K Buy
+100,000
New +$99.4K 0.02% 177

Other funds holding ONCY

IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 22.25% 1-Year Est. Return
Everhart Financial Group
Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Badgley Phelps Wealth Managers
Badgley Phelps Wealth Managers Seattle, Washington $5.8B AUM 25.34% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
StoneX Group
StoneX Group New York $2.75B AUM 24.25% 1-Year Est. Return
Professional Advisory Services
Professional Advisory Services Vero Beach, Florida $837M AUM 20.44% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return
D.A. Davidson & Co
D.A. Davidson & Co Great Falls, Montana $18.6B AUM 17.65% 1-Year Est. Return
Ball & Co Wealth Management
Ball & Co Wealth Management Franklin, Tennessee $147M AUM 15.82% 1-Year Est. Return

Doliver Advisors's ONCY Position: Q3 2026 in Review

Doliver Advisors held its Oncolytics Biotech (ONCY) position steady in Q3 2026 at 100,000 shares worth $66.8K. The position accounts for 0.01% of the portfolio, ranked #181.

Doliver Advisors first reported a position in ONCY in Q1 2026 and has held it in 3 quarters since. The position peaked at $95K in Q2 2026. 26 funds tracked by Wall St. Rank hold ONCY as of Q3 2026.

  • Doliver Advisors held 100,000 shares of Oncolytics Biotech worth $66.8K as of Q3 2026.
  • Doliver Advisors left its Oncolytics Biotech share count unchanged in Q3 2026.
  • Oncolytics Biotech made up 0.01% of Doliver Advisors's portfolio in Q3 2026, its #181 holding.
  • Doliver Advisors first reported a position in Oncolytics Biotech in Q1 2026 and has held it in 3 quarters since.
  • Doliver Advisors's Oncolytics Biotech position peaked at $95K in Q2 2026.
  • 26 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q3 2026.

Based on Doliver Advisors's 13F filing for Q3 2026, filed 1 Oct 2026.